NTRA vs SRTA
NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health. SRTA: A time-critical logistics and clinical services provider offering integrated air/ground organ transport, surgical organ recovery, and cardiac perfusion solutions to the U.S. transplant ecosystem.
Side-by-side fundamentals
| Metric | NTRA | SRTA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $264.22 | $5.08 | |
| Market cap as of 2026-07-23 | $37.9B | $438M | |
| P/E as of 2026-07-23 | n/a | 9.33 | |
| PEG as of 2026-07-23 | -13.63 | n/a | |
| Net margin as of 2026-07-23 | -9.1% | +18.5% | SRTA higher |
| Gross margin as of 2026-07-23 | +65.1% | -39.7% | NTRA higher |
| Operating margin as of 2026-07-23 | -13.0% | -7.8% | SRTA higher |
| ROE as of 2026-07-23 | -15.1% | +17.5% | SRTA higher |
| ROA as of 2026-07-23 | -10.5% | +15.1% | SRTA higher |
| Debt / equity as of 2026-07-23 | 0.05 | 0.00 | SRTA lower |
| Revenue growth (YoY) as of 2026-07-23 | +36.6% | +19.6% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +10.5% | NTRA higher |
| Beta as of 2026-07-23 | 1.54 | 2.27 | |
| 1-year return as of 2026-07-22 close | +88.8% | +12.4% | NTRA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.